Compare Crispr Therapeutics AG (CRSP) vs ProShares UltraShort Bloomberg Natural Gas ETF (KOLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs ProShares UltraShort Bloomberg Natural Gas ETF — how do they compare? Crispr Therapeutics AG trades at $53.9 (market cap $5.23B), while ProShares UltraShort Bloomberg Natural Gas ETF trades at $28.01. The key difference: ProShares UltraShort Bloomberg Natural Gas ETF is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | KOLD | |
|---|---|---|
Market Cap | $5.23B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $76.78 | $49.39 |
52-Week Low | $44.34 | $13.58 |
Enterprise Value | $3.65B | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About ProShares UltraShort Bloomberg Natural Gas ETF
KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.
Read more on KOLD →
